- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
January 5th, 2005
As nanotechnology companies move into public markets, early stage companies may lack the revenue visibility usually accompanying startups in more established industries.
It is arguable that a platform technology-based nanotechnology company what well call pluripotent deserves a premium valuation: one that exceeds the value of its visible product line. But as shown by the withdrawn IPO of Nanosys an example of this type of company public investors may not see it this way.
|Related News Press|
Nanotech Grants Options September 22nd, 2016
Arrowhead Pharmaceuticals to Present at Upcoming September Conferences September 1st, 2016
Industrial Nanotech, Inc. Provides Shareholder Update August 22nd, 2016